gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Luiz Eduardo WildembergDaniel HenriquesPaula Condé Lamparelli EliasCarlos Henrique de A LimaNina R de Castro MusolinoAline Helen Silva CamachoOlivia FariaDebora NazatoJulio AbuchamLucio Vilar Rabelo FilhoJose Italo MotaMartha Katherine P HuayllasLeila ChimelliMargaret de CastroLeandro K J de PinhoMônica R GadelhaPublished in: Cancers (2021)
In this largest series available in the literature, we concluded that gsp is not a molecular biomarker of response to fg-SRL treatment in acromegaly. However, the importance of its negative association with cavernous sinus invasion and SST5 expression needs to be further investigated.